Quest Diagnostics Incorporated (dgx)

DGX — Company Overview

Quest Diagnostics Incorporated (DGX) trades on NYQ as part of the Healthcare peer group (Diagnostics & Research).

DGX — Business Description

DGX represents a Diagnostics & Research business in the Healthcare segment. Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides services under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers commercial clinical laboratories, and accountable care organizations through a network of laboratories, patient service centers, phlebotomis…

Official website: https://www.questdiagnostics.com.

DGX — Investment Thesis

At a high level, DGX offers exposure to Healthcare with metrics outlined below from public market data.

• Revenue is expanding at roughly 10.2% year-over-year (public data).
• Trailing P/E of 25.77× sits in a moderate band relative to high-growth peers.
• Forward P/E (19.32×) is below trailing P/E — earnings may be expected to improve.
• Dividend yield near 1.5% adds an income component to total return.
• Equity market capitalization is approximately $25.72B.

See the free estimates and earnings pages for public targets and growth metrics. Ownership, live news, and deeper models remain in Vest Terminal.

DGX — Financial Health

Key financial health indicators for Quest Diagnostics Incorporated are derived exclusively from public data — no proprietary estimates.

Profit margin near 9.2% leaves a narrower cushion versus higher-margin peers. Positive free cash flow of $909.63M supports balance-sheet flexibility.

DGX — Growth Outlook

Growth outlook for Quest Diagnostics Incorporated (DGX) depends on demand trends in Diagnostics & Research and the company's ability to convert revenue into sustainable earnings.

• Revenue growth of 10.2% indicates strong top-line momentum.
• Earnings growth of 15.0% year-over-year supports improving profitability.
• Price is 6.4% below the 52-week high.

DGX — Competitive Position

Quest Diagnostics Incorporated (DGX) is evaluated against peers on scale, margin structure, and capital efficiency within Healthcare.

• Competes within Healthcare, specifically in Diagnostics & Research.
• Market capitalization of $25.72B places DGX among large-cap peers.
• Gross margin of 33.2% should be benchmarked against direct competitors.

DGX — Summary

Quest Diagnostics Incorporated (DGX) is a large-cap Healthcare company focused on Diagnostics & Research, listed on NYQ. Last price $233.00 with market cap $25.72B. Trailing P/E 25.77×. Revenue grew 10.2% year-over-year per public data. Notable strengths include revenue growth of 10.2% year-over-year. Premium Terminal tools for Quest Diagnostics Incorporated add ownership analytics, news, and richer estimate history beyond this public summary.